HMGB1

High mobility group protein B1 · P09429 · HMGB1 on Sugi Atlas →

25,444 patent compounds predicted against HMGB1, 19,979 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydroxytoluic Acid (SCHEMBL25756)	0.48	3/20
SCHEMBL23708	0.47	3/20
Hydroxytoluic Acid (SCHEMBL238307)	0.47	3/20
SCHEMBL40166	0.42	3/20
Quercitrin (SCHEMBL117644)	0.84	2/20
Quercitrin (SCHEMBL147092)	0.84	2/20
Quercitrin (SCHEMBL147093)	0.84	2/20
SCHEMBL24608	0.73	2/20
Reynoutrin (SCHEMBL38138)	0.69	2/20
Reynoutrin (SCHEMBL151757)	0.69	2/20
SCHEMBL248816	0.66	2/20
2,3-Dihydroxybenzoic Acid (SCHEMBL37458)	0.65	2/20
SCHEMBL39623	0.65	2/20
SCHEMBL180904	0.64	2/20
Bicarbonate (SCHEMBL237485)	0.62	2/20
Salsalate (SCHEMBL15562)	0.61	2/20
SCHEMBL5459	0.60	2/20
SCHEMBL88229	0.60	2/20
Phthalic Acid (SCHEMBL2777)	0.59	2/20
SCHEMBL110532	0.59	2/20

Clinical trials — most relevant to HMGB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery	PHASE1/PHASE2	COMPLETED
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients	PHASE2	ACTIVE_NOT_RECRUITING
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma	PHASE1/PHASE2	COMPLETED
The Benefit of Bermekimab in Patients With Systemic Sclerosis	PHASE2	COMPLETED
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia	PHASE2	COMPLETED
Markers of Tissue Injury and Rhabdomyolysis in Patients With Major Trauma	nan	COMPLETED
Post-surgery Systemic Inflammation and Neuro-immune Interactions	nan	COMPLETED
Histochemical Study of Vitiligo in Sohag University Hospital Patients	nan	UNKNOWN
EVALUATION OF SALIVARY BİOMARKER LEVELS IN SMOKING AND NON-SMOKER INDIVIDUALS WITH DIFFERENT PERIODONTAL DISEASES	nan	COMPLETED
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction	nan	COMPLETED
The White Blood Cell Reactivity Following Surgical Trauma and Associated Regulatory Mechanisms.	nan	COMPLETED
Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients	nan	COMPLETED
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)	nan	RECRUITING
HMGB1 in ICU-survivors	nan	COMPLETED
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study	nan	COMPLETED
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Valvular Heart Surgery	nan	COMPLETED
Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium	nan	WITHDRAWN
Macrophage Inhibitory Factor and High-Mobility Group-1 Protein in Children Undergoing Cardiopulmonary Bypass	nan	COMPLETED
Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE).	nan	COMPLETED
Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient	nan	COMPLETED
Preoperative Risk Factors and Perioperative Neurocognitive Disorders	nan	COMPLETED
Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System	nan	COMPLETED
Detection of Circulating Biomarkers of Immunogenic Cell Death	nan	COMPLETED
HMGB1 Release From Hemorrhagic Shock Patients	nan	COMPLETED
The Influence of Ventilation on Perioperative Neurocognitive Disorders	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HMGB1 binder may also engage these)

Protein	Name	Similarity
P10103	—	1.000	P10103 →
B0CM99	—	1.000	B0CM99 →
Q08IE6	—	1.000	Q08IE6 →
Q4R844	—	1.000	Q4R844 →
B1MTB0	—	1.000	B1MTB0 →
A9RA84	—	1.000	A9RA84 →
Q6YKA4	—	1.000	Q6YKA4 →
P12682	—	1.000	P12682 →
P63159	—	1.000	P63159 →
P63158	—	1.000	P63158 →
P07156	—	1.000	P07156 →
Q9YH06	—	1.000	Q9YH06 →
B2RPK0	—	1.000	B2RPK0 →
O54879	—	1.000	O54879 →
HMGB3	High mobility group protein B3	1.000	landscape →
P26584	—	1.000	P26584 →
P17741	—	1.000	P17741 →
P40673	—	0.999	P40673 →
P40618	—	0.999	P40618 →
P30681	—	0.998	P30681 →
HMGB2	High mobility group protein B2	0.996	landscape →
P52925	—	0.996	P52925 →
Q32L31	—	0.996	Q32L31 →
P07746	—	0.993	P07746 →
Q05783	—	0.990	Q05783 →
Q06943	—	0.990	Q06943 →
P40644	—	0.990	P40644 →
P0CO24	—	0.988	P0CO24 →
P11873	—	0.988	P11873 →
P40625	—	0.988	P40625 →